Zhejiang Hisoar Pharmaceutical Co., Ltd. (stock code 002099, Shenzhen Exchange), founded in 1966 and headquartered in Taizhou, Zhejiang, China, is a diversified pharmaceutical and chemical company with ~3,000 employees and 426 R&D personnel. Their pharmaceutical division produces specialty APIs, intermediates, formulations, and fine chemicals -- specifically antibiotics (penem/carbapenem series, clindamycin series), cardiovascular agents, and anti-diabetic APIs. Over 70% of products are exported. They also have a major dye/pigment business segment (~70% global market share in Reactive Blue KN-R). The company has 3 FDA-registered FEI numbers for API manufacture, 7 FDA inspections (4 NAI, 3 VAI, 0 OAI), 2 FDA-approved products (capsule, tablet), 40+ invention patents, and partnerships with Boehringer Ingelheim, Merck, Sanofi, Novartis, GSK, and others. Classified as API manufacturer because the core pharma business is own-brand API and intermediate production with limited CDMO positioning, though PharmaSource lists them under CMO/CDMO.
carbapenem/penem antibiotics API, clindamycin series, anti-diabetic APIs, chiral drug intermediates, large-scale chemical synthesis
1 site worldwide
Involvement in 1 clinical trial
No reviews available yet.
No documents available.